BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Editas and Vertex Ink Deal for Cas9 License for $50M Upfront

  December 13, 2023

   · 

  1 min read
• 

  Business

  Pfizer’s 2024 Outlook Disappoints Wall Street, Plans $500M in Additional Cost Cuts

  The biopharma giant provided full-year 2024 guidance on Wednesday that fell below Wall Street’s expectations, as it continues a cost-cutting effort now up to $4 billion in total.

  December 13, 2023

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Career Advice

  How to Assess a Company’s DEI Commitment as a Candidate

  Here’s what to look for—and what to ask—before and during the interview process to find out whether an employer fosters an inclusive environment.

  December 13, 2023

   · 

  3 min read

   · 

  Nadia Bey
• 

  How to Cope with Layoffs and Other Career Setbacks

  Being laid off, experiencing a trial failure or failing to secure funding can feel crushing. Here’s how to maintain perspective and move on.

  December 13, 2023

   · 

  4 min read

   · 

  Mollie Barnes
• 

  Policy

  MAPS PBC Submits First NDA to FDA for Psychedelic-Assisted Therapy

  If approved by the FDA, the MDMA-assisted treatment for individuals with post-traumatic stress disorder would be the first U.S. psychedelic-assisted therapy.

  December 13, 2023

   · 

  2 min read

   · 

  Joanna Smiley
• 

  Policy

  EU Lists Hundreds of Critical Medicines in Effort to Prevent Shortages

  Medicines on the list can still be prescribed but will be under tight monitoring by a regulatory network, which can implement measures to prevent shortages and ensure supply chain continuity.

  December 13, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  J&J, Genmab Unveil Darzalex Faspro Data with Eye Toward Earlier Multiple Myeloma Lines

  Johnson & Johnson and Genmab revealed the first data from a Phase III study of a Darzalex Faspro-based quadruplet therapy in patients with transplant-eligible newly diagnosed multiple myeloma.

  December 13, 2023

   · 

  2 min read

   · 

  Tyler Patchen
• 

  As Its Domestic Market Grows, South Africa Moves Toward Greater Local Biopharmaceutical Production

  Partnerships with companies based in the U.S. and elsewhere are one factor driving growth in the industry, but obstacles remain.

  December 13, 2023

   · 

  5 min read

   · 

  Patience Asanga
• 

  Policy

  FDA Action Alert: Calliditas, Ionis/AstraZeneca, Amgen and More

  The year may be coming to a close, but there’s no holiday break for the FDA, which will release five regulatory verdicts over the next two weeks.

  December 13, 2023

   · 

  4 min read

   · 

  Tristan Manalac
• 

  FDA

  Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny

  This week, we discuss the two major FDA approvals for sickle cell from Vertex/CRISPR and bluebird bio; Axcella and the future of long-covid treatments, Vanda’s $100m purchase and AI regulatory developments in Europe.

  December 13, 2023

   · 

  1 min read

   · 

  Lori Ellis